ELX-02
Phase 2Small molecule
ELX-02 is one of 49 small molecule programs targeting Cystinosis. It is currently in Phase 2.
3
Indications
8
Total Trials
0
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
386 competitors in Cystic Fibrosis
#DrugCompanyPhaseTrials
1Onglyza
AstraZenecaPreclinical
ELX-02
EEloxx Pharmaceuticals, Inc.
Phase 2
Calciferol
Alnylam PharmaceuticalsPreclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Proair HFA
GGlaxo Dba Glaxosmithkline
Preclinical
Actimmune
HHorizon Therapeutics Ireland DAC
Preclinical
Advil
KKenvue Brands
Preclinical
Tums
OtsukaPreclinical
Feosol
AAuerbach Hematology Oncology Associates P C
Preclinical
Capromorelin
UUniversity of Aarhus
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Cystic Fibrosis2 trials
Renal Impairment1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ELX-02. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- EEloxx Pharmaceuticals, Inc.